Eli Lilly and Company $LLY Stock: Hager Investment Management Services LLC Trims Holdings

Hager Investment Management Services LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,200 shares of the company’s stock after selling 393 shares during the quarter. Eli Lilly and Company makes up approximately 2.3% of Hager Investment Management Services LLC’s holdings, making the stock its 9th biggest holding. Hager Investment Management Services LLC’s holdings in Eli Lilly and Company were worth $4,860,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Coastal Bridge Advisors LLC bought a new position in shares of Eli Lilly and Company in the 2nd quarter worth $2,959,000. Birinyi Associates Inc. increased its holdings in Eli Lilly and Company by 32.6% in the third quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock valued at $1,689,000 after purchasing an additional 359 shares during the last quarter. Mosaic Family Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after buying an additional 1,430 shares during the last quarter. Heritage Investors Management Corp grew its position in shares of Eli Lilly and Company by 6.5% during the 3rd quarter. Heritage Investors Management Corp now owns 11,774 shares of the company’s stock worth $13,624,000 after buying an additional 718 shares during the period. Finally, Moran Wealth Management LLC grew its position in shares of Eli Lilly and Company by 85.6% during the 2nd quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock worth $25,072,000 after buying an additional 9,638 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.3%

Shares of NYSE:LLY opened at $1,372.15 on Monday. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,453.00. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The company’s fifty day simple moving average is $1,215.24 and its 200 day simple moving average is $1,101.16. The firm has a market cap of $1.29 trillion, a price-to-earnings ratio of 44.54, a PEG ratio of 1.62 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period in the prior year, the business earned $7.02 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.

Insider Buying and Selling

In related news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by company insiders.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Analyst Ratings Changes

A number of analysts have recently commented on the company. HSBC upped their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research note on Thursday, September 10th. BMO Capital Markets reissued an “outperform” rating and set a $1,650.00 price objective on shares of Eli Lilly and Company in a research note on Friday, October 30th. Citigroup boosted their price objective on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a report on Friday, October 30th. UBS Group upped their target price on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Finally, Bank of America reiterated a “buy” rating and issued a $1,497.00 target price on shares of Eli Lilly and Company in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,404.14.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.